Evidence map›Paper›PMID 35236263›Full record

ArticleCurrent neuropharmacology2022

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort.

Mengjuan Xing, Jialing Sheng, Mengxin Cui, Yousong Su, Chengfang Zhang, Xi Chen, Yu Fang, Donghong Cui, Zezhi Li

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mengjuan XingShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Jialing ShengThe First Minzheng Mental Health Center. Shanghai, China.
Mengxin CuiQingdao Mental Health Center, Qingdao University, Qingdao, China.
Yousong SuShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Chengfang ZhangShanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China.
Xi ChenShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Yu FangShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Donghong CuiShanghai Mental Health Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Zezhi LiDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.
Shanghai Jiao Tong University · CNGuangzhou Medical University · CNQingdao Mental Health Center · CNShanghai Mental Health Center · CNTongji University · CN

Funding

National Key Research and Development Program 2017YFC0909200National Natural Science Foundation of China 81671336Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Special Project 21Y11921200
6 · The paper itself

Abstract

backgroundAntipsychotics are known to be associated with metabolic syndromes (MetS). Chlorpromazine (CPZ) and Clozapine (CLZ) are currently the most commonly used antipsychotics in low-income districts of China. However, potential differences in the long-term effects of CPZ and CLZ on MetS in schizophrenia inpatients are not well understood. Here, we aimed to identify any MetS profile differences between long-term schizophrenia patients who were prescribed either CPZ or CLZ at a primary psychiatric hospital.

methodsWe recruited a total of 204 male schizophrenia patients who received either CPZ or CLZ. We measured their weight, height, body mass index (BMI), waist circumference (WC), diastolic blood pressure (DBP), and systolic blood pressure (SBP), as well as their biochemical indicators, including fasting blood glucose (FBS), triglycerides (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c).

resultsThe MetS prevalence in the CPZ and CLZ groups was 31% and 37.5%, respectively. The CLZ group had significantly higher DBP levels and a higher incidence of dyslipidemia (HDL-c) but lower HDL-c and TC levels than the CPZ group. We also determined that smoking history, BMI, and duration of hospitalisation were risk factors for the development of MetS. Moreover, we found that CPZ and CLZ were correlated with the same risk for developing MetS and that BMI was a vital risk factor of MetS for both the CPZ and CLZ groups.

conclusionLong-term CPZ and CLZ prescriptions were associated with similar profiles for developing MetS of schizophrenia patients.

Indexed as

Antipsychotic AgentsClozapineMetabolic SyndromeChlorpromazineCholesterolCholesterol, HDLHumansMalePrevalenceRetrospective StudiesRisk FactorsAntipsychotic AgentsChlorpromazineCholesterolCholesterol, HDLClozapineantipsychoticsdiabetesdyslipidemiametabolic syndromeretrospective cohort studySchizophrenia

Identifiers

PMID35236263
PMCPMC9886797
OpenAlexW4214873452

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.